Figure 4.

Change in FEV₁ (% predicted) from baseline through cycle 6 of Arikace. Each cycle consisted of 28 days of once daily Arikace (560 mg) followed by 56 days off study drug. Each shaded box is a treatment cycle. Study days (every 2 weeks) are as shown on the abscissa, with the number of subjects at each time point as noted immediately above the study days. *p<0.0001 for FEV₁ at end of treatment following six cycles compared with baseline; **p=0.0001 for FEV₁ at 56 days post-treatment following six cycles compared with baseline.